SH2D3C and COVID-19: Bortezomib is a proteasome inhibitor that has been proposed as COVID-19 therapy given its capacity to inhibit (although only marginally) the papain-like protease (NSP3) of SARS-CoV, which also has deubiquitinase activity73–75.